A phase I and pharmacologic study of the proteasome inhibitor PS-341 [bortezomib] in combination with paclitaxel and carboplatin in patients with advanced malignancies.

Trial Profile

A phase I and pharmacologic study of the proteasome inhibitor PS-341 [bortezomib] in combination with paclitaxel and carboplatin in patients with advanced malignancies.

Completed
Phase of Trial: Phase I

Latest Information Update: 15 Jan 2013

At a glance

  • Drugs Bortezomib (Primary) ; Carboplatin; Paclitaxel
  • Indications Solid tumours
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 05 Nov 2008 Actual end date (Apr 2006) added as reported by ClinicalTrials.gov.
    • 05 Nov 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 18 Sep 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top